
## Tufia C Haddad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1545658/publications.pdf Version: 2024-02-01



Τιίεια C Ηλοράρ

#	Article	IF	CITATIONS
1	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 282-293.	0.8	88
2	Aurora-A Kinase as a Promising Therapeutic Target in Cancer. Frontiers in Oncology, 2015, 5, 295.	1.3	76
3	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 6823-6832.	3.2	66
4	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. Journal of Clinical Oncology, 2020, 38, 1409-1418.	0.8	64
5	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Research, 2018, 20, 105.	2.2	58
6	Function, Shoulder Motion, Pain, and Lymphedema in Breast Cancer With and Without Axillary Web Syndrome: An 18-Month Follow-Up. Physical Therapy, 2018, 98, 518-527.	1.1	48
7	Landscape of Neoadjuvant Therapy for Breast Cancer. Annals of Surgical Oncology, 2015, 22, 1408-1415.	0.7	47
8	Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19. Npj Digital Medicine, 2021, 4, 123.	5.7	42
9	A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 1221-1227.	1.1	39
10	Updates in the Evaluation and Management of Breast Cancer. Mayo Clinic Proceedings, 2018, 93, 794-807.	1.4	39
11	Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 842-851.	1.8	36
12	Aurora-A kinase oncogenic signaling mediates TGF-Î <sup>2</sup> -induced triple-negative breast cancer plasticity and chemoresistance. Oncogene, 2021, 40, 2509-2523.	2.6	34
13	Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer, 2016, 122, 378-385.	2.0	31
14	MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Academic Radiology, 2022, 29, S145-S154.	1.3	31
15	Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells. PLoS ONE, 2014, 9, e96995.	1.1	30
16	Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval. JMIR Cancer, 2018, 4, e10.	0.9	27
17	Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer. Current Breast Cancer Reports, 2017, 9, 173-182.	0.5	26
18	Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 449-458.	0.8	25

Tufia C Haddad

#	Article	IF	CITATIONS
19	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. Oncotarget, 2017, 8, 91803-91816.	0.8	23
20	Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot Study. JMIR Medical Informatics, 2021, 9, e27767.	1.3	23
21	Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 639-647.	1.1	21
22	Managing Patients in the COVID-19 Pandemic. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 118-126.	1.2	20
23	Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005984.	0.9	18
24	Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. JCO Oncology Practice, 2021, 17, e1293-e1302.	1.4	18
25	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α. Clinical Cancer Research, 2020, 26, 2986-2996.	3.2	17
26	Clinical performance pilot using cognitive computing for clinical trial matching at Mayo Clinic Journal of Clinical Oncology, 2018, 36, e18598-e18598.	0.8	17
27	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 163, 535-544.	1.1	16
28	New-Onset Heart Failure in Association With Severe Hypertension During Trastuzumab Therapy. Mayo Clinic Proceedings, 2014, 89, 1734-1739.	1.4	13
29	A Scalable Framework for Telehealth: The Mayo Clinic Center for Connected Care Response to the COVID-19 Pandemic. Telemedicine Reports, 2021, 2, 78-87.	0.5	13
30	Novel approaches to support breast cancer survivorship care models. Breast, 2017, 36, 1-13.	0.9	11
31	Pilot implementation to assess the feasibility and care team impact of an app-based interactive care plan to remotely monitor breast cancer survivors. Journal of Cancer Survivorship, 2022, 16, 13-23.	1.5	10
32	Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Research and Treatment, 2017, 164, 515-525.	1.1	9
33	Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. Critical Reviews in Oncology/Hematology, 2020, 156, 103093.	2.0	9
34	Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3329-3338.	3.2	8
35	Avoiding the "Faux Equalizer― Mayo Clinic Proceedings, 2021, 96, 2963-2965.	1.4	7
36	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 18.	0.4	6

Tufia C Haddad

#	Article	IF	CITATIONS
37	Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer. Case Reports in Oncology, 2016, 9, 33-38.	0.3	6
38	Aurora-A overexpression is linked to development of aggressive teratomas derived from humans iPS cells. Oncology Reports, 2018, 39, 1725-1730.	1.2	5
39	Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). Breast Cancer Research and Treatment, 2021, 188, 477-487.	1.1	5
40	Five-Year Cumulative Incidence of Axillary Web Syndrome and Comparison in Upper Extremity Movement, Function, Pain, and Lymphedema in Survivors of Breast Cancer With and Without Axillary Web Syndrome. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1798-1806.	0.5	5
41	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. Blood, 2021, 138, 568-568.	0.6	4
42	Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens. Clinical Breast Cancer, 2018, 18, e513-e520.	1.1	1